Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients - 11/09/11
From the Clinical Research Department, Janssen Research Foundation, Beersea; the Department of Dermatology, College of Physicians and Surgeons, Columbia University, New Yorkb; the Nail Disease Center, Cannesc; Mouscrond; the Department of Dermatology, U. Z. Saint-Rafael Catholic University, Leuvene; the Department of Dermatology, Free University of Brussels, Jettef; Turkuf; the Department of Dermatology, Baylor College of Medicine, Houstonh; the Department of Dermatology, University of Torontoi; the Department of Dermatopathology, CHU Sart Tilman, University of Liege.j
Abstract |
Background: Onychomycosis of the toenail caused by nondermatophyte molds alone or in combination with dermatophytes is difficult to eradicate with standard antifungal therapy.
Objective: Our purpose was to determine the effectiveness of itraconazole in the treatment of toenail onychomycosis caused by molds alone or in combination with dermatophytes.
Methods: We treated 36 patients with this drug given as continuous dosing (100 or 200 mg/day) for 6 to 20 weeks or as a 1-week pulse dosing (200 mg twice daily for 1 week per month) for two to four pulses.
Results: Patients with toenail onychomycosis with the following organisms were treated: Aspergillus spp. (eight patients), Fusarium spp. (four patients), Scopulariopsis brevicaulis (23 patients), and Alternaria spp. (one patient). Nineteen patients had onychomycosis with a mixed origin. At follow-up, 12 months after therapy was initiated, clinical and mycologic cure was achieved in 15 of 17 patients (88%) with onychomycosis caused by a single mold. In patients with mixed infection, a clinical cure was obtained in 16 of 19 patients (84%) and a mycologic cure in 13 of 19 patients (68%).
Conclusion: Itraconazole appears to be effective and safe for the treatment of toenail onychomycosis caused by some nondermatophyte molds alone or in combination with dermatophytes.
(J Am Acad Dermatol 1997;36:173-7.)
Le texte complet de cet article est disponible en PDF.Plan
 | Reprint requests: Piet De Doncker, PhD, Clinical Research, Janssen Research Foundation, Turnhoutseweg, 30, B-2340 Beerse, Belgium. |
| 0190-9622/97/$5.00 + 0 16/1/77697 |
Vol 36 - N° 2
P. 173-177 - février 1997 Retour au numéro
Article précédent
- Antiphospholipid antibodies and the antiphospholipid antibody syndrome
- George T. Nahass, From the Department of Dermatology, St. Louis University Health Sciences Center.
- Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea
- Mazen S. Daoud, Lawrence E. Gibson, Mark R. Pittelkow, From the Department of Dermatology, Mayo Clinic and Mayo Foundation.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?